8-K: Zynex Q3 Revenue Plunges, Misses Debt Payment

Zynex, Inc. reported a significant decline in third-quarter 2025 revenue and a substantial net loss, leading to a missed interest payment on its convertible notes and a strategic review of its financial future.

Summary

• Net revenue for Q3 2025 was $13.4 million, a sharp decrease from $50.0 million in Q3 2024.
• The company reported a net loss of ($42.9) million, or ($1.42) per basic and diluted share, for Q3 2025, compared to a net income of $2.3 million, or $0.07 per share, in Q3 2024.
• Adjusted EBITDA loss for Q3 2025 was ($12.3) million, a significant drop from Adjusted EBITDA of $5.1 million in Q3 2024.
• Gross profit decreased to $8.1 million (60% of revenue) in Q3 2025 from $39.8 million (80% of revenue) in Q3 2024.
• A non-cash asset impairment charge of $30.7 million was recorded in Q3 2025, primarily related to goodwill, definite-lived intangible assets, and certain fixed assets.
• Cash and cash equivalents stood at $13.3 million as of September 30, 2025, down from $39.6 million at December 31, 2024.
• Cash flow from operations for the three and nine months ended September 30, 2025, was ($6.3) million and ($23.0) million, respectively.
• Zynex has entered a 30-day grace period by not making a $1.5 million interest payment due November 17, 2025, on its $60 million Convertible Notes maturing in May 2026.
• The company has engaged Province, LLC to evaluate strategic alternatives, including potential capital raising, recapitalization, and restructuring strategies.
• A Special Committee of the Board of Directors has been formed, chaired by new board member Paul Aronzon, to oversee the assessment and implementation of strategic alternatives.

Sentiment

Score: 1

Explanation: The sentiment is extremely negative due to a massive decline in revenue, significant net loss, negative cash flow, and the critical decision to miss an interest payment on convertible notes, signaling severe financial distress and potential default. While management is taking steps, the current financial state is dire.

Positives

• The new management team, led by CEO Steven Dyson, is focused on a three-part strategy: renewing commitment to compliance and integrity, addressing liquidity challenges, and improving revenue and cash flow performance.
• Engagement of Province, LLC, an internationally recognized financial advisory firm, to assist in evaluating strategic alternatives, including capital raising and restructuring.
• Appointment of Paul Aronzon to the Board of Directors and as Chair of a Special Committee to oversee strategic alternatives, indicating proactive governance in addressing challenges.

Negatives

• Net revenue declined significantly to $13.4 million in Q3 2025 from $50.0 million in Q3 2024, primarily due to Tricare payment suspension and changes to payer claim practices.
• The company reported a substantial net loss of ($42.9) million for Q3 2025, a stark contrast to net income of $2.3 million in the prior year quarter.
• Adjusted EBITDA turned negative, with a loss of ($12.3) million in Q3 2025 compared to a positive $5.1 million in Q3 2024.
• A non-cash asset impairment charge of $30.7 million was recognized in Q3 2025, reflecting a significant write-down of assets.
• Cash and cash equivalents decreased to $13.3 million as of September 30, 2025, from $39.6 million at the end of 2024, indicating significant cash burn.
• Negative cash flow from operations of ($6.3) million for Q3 2025 and ($23.0) million for the nine months ended September 30, 2025.
• The company elected to enter a 30-day grace period by not making a $1.5 million interest payment on its $60 million Convertible Notes, signaling severe liquidity issues and potential default.
• Workforce reductions in the first and second quarters of 2025 negatively impacted device orders, supplies, new patient onboarding, and order completion.

Risks

• There is no assurance that any strategic transaction will result from the Special Committee's evaluation of strategic alternatives, or regarding the timing, terms, and conditions of any such transaction.
• The company's ability to raise capital or otherwise improve its liquidity position and continue as a going concern is uncertain.
• The outcome of legal proceedings and regulatory investigations in which the company is involved could negatively impact operations.
• Dependence on the reimbursement for products from health insurance companies, including the outcome of the Tricare payment suspension, poses a significant risk.
• The need to obtain CE marking for new products and the acceptance of the company's products by doctors and hospitals are critical for future growth.
• Competition from larger competitors with greater financial resources could hinder market penetration and growth.
• The need to keep pace with technological changes is essential for maintaining product relevance and competitiveness.
• Dependence on third-party manufacturers to produce products on time and to specifications introduces supply chain risks.
• Market conditions and economic factors, such as interest rate fluctuations, could adversely affect financial performance.

Future Outlook

Management is committed to rebuilding and returning the company to growth in the future, focusing on compliance, liquidity, and improving revenue and cash flow. The company is actively evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies, though there is no assurance any such transaction will result.

Management Comments

• "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company." Steven Dyson, CEO
• "We have been focused on a three-part strategy: renewing our commitment to compliance and integrity, addressing the company's current liquidity challenges, and improving revenue and cash flow performance."
• "While the Third Quarter of 2025 was more of a continuation of first-half performance, we have seen progress with our strategy and we remain committed to rebuild and return the company to growth in the future."
• "We are taking decisive steps to ensure Zynex is well-positioned going forward." Steven Dyson, CEO
• "The engagement of Province and the formation of the Special Committee reflect our commitment to exploring all avenues to create a new future for Zynex."

Industry Context

Zynex operates in the medical technology sector, specializing in non-invasive devices for pain management, rehabilitation, and monitoring systems. The company's current challenges, particularly the Tricare payment suspension and changes in payer claim practices, highlight the significant impact of reimbursement policies and regulatory compliance on companies in this industry. While the filing does not detail broader industry trends, the issues faced by Zynex appear to be company-specific, stemming from internal compliance and liquidity problems, rather than a general downturn in the medical device market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for a direct assessment against global benchmarks.
• However, the reported financial performance, including a significant revenue decline of over 73% year-over-year and a substantial net loss, is drastically below typical industry standards for healthy, growing medical technology companies.
• Negative Adjusted EBITDA and cash flow from operations, coupled with a missed debt payment, indicate severe financial distress that is not characteristic of well-performing peers in the medical device sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings and regulatory investigations, the outcome of which is a risk factor, though no specific details are provided in this filing.

Stakeholder Impact

• Shareholders face significant risk of value erosion due to the severe financial decline, potential dilution from capital raises, and uncertainty surrounding the company's future.
• Convertible Note holders are directly impacted by the missed interest payment and face potential restructuring or default scenarios for their $60 million investment.
• Employees have already experienced workforce reductions and may face further uncertainty regarding job security as the company evaluates restructuring options.
• Customers may experience concerns regarding product availability or service continuity if the company's financial challenges persist or escalate.
• Suppliers and creditors may face increased credit risk and potential delays in payments due to the company's liquidity challenges.

Next Steps

• The Special Committee, in conjunction with management, Province, LLC, and counsel, will assess and implement strategic alternatives, including potential capital raising, recapitalization, and restructuring.
• Discussions are ongoing with an ad hoc group of Convertible Note holders regarding potential restructuring opportunities.
• An earnings call is scheduled for Tuesday, November 18, 2025, at 9:00 AM Eastern Time to discuss the Q3 2025 financial results.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, marked by a drastic revenue decline, substantial net loss, negative cash flow, and the critical decision to miss an interest payment on its convertible notes. This indicates a high risk of default and potential bankruptcy. While management is exploring strategic alternatives, the immediate outlook is highly uncertain and negative. Investors should consider exiting their positions to avoid further losses.

Keywords

Zynex, ZYXI, Q3 2025, financial results, net loss, revenue decline, Adjusted EBITDA, convertible notes, debt default, strategic alternatives, capital raise, restructuring, Tricare, medical technology, pain management, rehabilitation, asset impairment